X4 Pharmaceuticals Files 8-K on Exit Costs and Personnel Changes

TL;DR

X4 Pharma filed an 8-K on 9/15/25 covering exit costs and exec changes.

AI Summary

On September 15, 2025, X4 Pharmaceuticals, Inc. filed an 8-K report detailing cost associated with exit or disposal activities, departure of directors or certain officers, and compensatory arrangements. The filing also includes information on Regulation FD Disclosure and Financial Statements and Exhibits.

Why It Matters

This filing indicates potential restructuring or strategic shifts within X4 Pharmaceuticals, which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — The filing mentions exit or disposal activities and changes in officers, which can signal financial distress or strategic uncertainty.

Key Players & Entities

• X4 Pharmaceuticals, Inc. (company) — Registrant
• September 15, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 001-38295 (company_id) — Commission File Number
• 27-3181608 (company_id) — IRS Employer Identification No.
• 61 North Beacon Street, 4th Floor Boston (address) — Business and Mail Address

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share XFOR The Nasdaq Stock Market
• $13 million — nnualized cost savings of approximately $13 million. The Company estimates that the workfor
• $3.3 million — ill incur cash charges of approximately $3.3 million for severance and other employee termin

Filing Documents

• xfor-20250915.htm (8-K) — 37KB
• ex991_2025916release.htm (EX-99.1) — 15KB
• image_0.jpg (GRAPHIC) — 21KB
• 0001501697-25-000021.txt ( ) — 207KB
• xfor-20250915.xsd (EX-101.SCH) — 2KB
• xfor-20250915_lab.xml (EX-101.LAB) — 23KB
• xfor-20250915_pre.xml (EX-101.PRE) — 13KB
• xfor-20250915_htm.xml (XML) — 3KB

05 Costs Associated with Exit or Disposal Activities

Item 2.05 Costs Associated with Exit or Disposal Activities. On September 17, 2025, X4 Pharmaceuticals, Inc. (the "Company" or "X4") announced a strategic restructuring designed to sharpen operational focus and align resources with the Company's longterm strategy to successfully complete the 4WARD Phase 3 trial in patients with moderate and severe chronic neutropenia. As part of this initiative, the Company will reduce its workforce by approximately 50%, a step anticipated to result in annualized cost savings of approximately $13 million. The Company estimates that the workforce reduction will be substantially completed in the third quarter of 2025. The Company estimates that it will incur cash charges of approximately $3.3 million for severance and other employee termination-related costs. The estimate of costs that the Company expects to incur related to the workforce reduction as well as the decrease in spending, and the timing thereof are subject to a number of assumptions and actual results may differ. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the actions described above. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Chief Operating Officer, Chief Commercial Officer, Chief Legal & Compliance Officer and Chief Medical Officer In connection with the workforce reduction discussed above, on September 15, 2025, the Board of Directors (the "Board") determined to terminate the employment of Dr. Mary DiBiase, the Company's Chief Operating Officer, Mark Baldry, the Company's Chief Commercial Officer, and Natasha Thoren, the Company's Chief Legal & Compliance Officer, in each case effective as of September 15, 2025. On September 16, 2025, Dr. Christophe Arbet-Engels informed the Company of his resignation as the Company's Chief Medica

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On September 17, 2025, the Company issued a press release titled "X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation," a copy of which is attached hereto as Exhibit 99.1. The information under this Item 7.01, including Exhibit 99.1 hereto, are being furnished herewith and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Forward-Looking Statements

Forward-Looking Statements This Form 8-K contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, without limitation, express or implied statements regarding the workforce reduction, including estimated costs, timing and expected benefits. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "target," "should," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including risks relating to the workforce reduction, such as the restructuring costs may be greater than anticipated, the restructuring may negatively impact the Company's business operations, the restructuring may not generate the intended benefits to the extent or as quickly as anticipated, and other risks and uncertainties described under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, which are on file with the SEC, and risks described in other filings that the Company makes with the SEC in the future. Any forward-looking statements contained in this Form 8-K speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 99.1 Press Release, dated September 17, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. X4 PHARMACEUTICALS, INC. Date: September 17, 2025 By: /s/ David H. Kirske Name: David H. Kirske Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR